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INTRODUCTION: Episodes of acquired bradykinin-mediated angioedema due to
angiotensin-converting enzyme (ACE) inhibitors may result in fatal outcomes.
There is no consensus regarding emergency pharmacological management of
these episodes. Treatment options include icatibant and C1INH concentrate.
Tranexamic acid is administered for moderate episodes. Its efficacy in the
treatment of ACE inhibitor-induced episodes of angioedema is not established. The
aim of this retrospective study is to assess the benefits of emergency tranexamic
acid administration in the management of ACE inhibitor-induced episodes of
angioedema.
METHODS: Retrospective analysis of the medical files of patients who consulted
between 2010 and 2016 in two French tertiary care hospitals for a bradykinic
angioedema attributed to an ACE treatment. All of them had received tranexamic
acid as a first line treatment.
RESULTS: Thirty three patients who had experienced severe episode of
angioedema were included. Twenty seven patients showed significant
improvement when treated with tranexamic acid alone. The six remaining patients
were treated with icatibant (5/33) or C1INH concentrate (1/33), due to partial
improvement after tranexamic acid therapy. None of the patients were intubated,
no fatalities were recorded and no side effects were reported.
CONCLUSION: Tranexamic acid is an easily accessible and affordable therapy
that may provide effective treatment for ACE inhibitor-induced episodes of
angioedema. It may help while waiting for a more specific treatment (icatibant
and C1INH concentrate) that is at times unavailable in emergency departments.
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